Current Biology, Volume 27

Supplemental Information

RTN3 Is a Novel Cold-Induced Protein and Mediates

Neuroprotective Effects of RBM3

Amandine Bastide, Diego Peretti, John R.P. Knight, Stefano Grosso, Ruth V. Spriggs, Xavier Pichon, Thomas Sbarrato, Anne Roobol, Jo Roobol, Davide Vito, Martin Bushell, Tobias von der Haar, C. Mark Smales, Giovanna R. Mallucci, and Anne E. Willis

| | - (| og | (p-va | lue) | | |
|--|-------------------------|----|--------|-------|-----|----|
| (| 0 1 | _ | 2 | 3 | 4 | |
| Cellular Assembly and Organization | | T | / | • | | |
| DNA Replication, Recombination, and Repair | | | | | | |
| Amino Acid Metabolism | | | | | | |
| Cell Death | | | | | | |
| Cell-To-Cell Signaling and Interaction | | | | | I | |
| Cell Cycle | ſ | 1 | | | | |
| Cell Signaling | | | | | | |
| Cellular Development | | | | | | |
| Cell Morphology | | ۲ | | | | |
| Cellular Growth and Proliferation | | | | | > | |
| Cellular Movement | | | | | | |
| Nucleic Acid Metabolism | | 1 | | I | | |
| RNA Post-Transcriptional Modification | | 4 | | | | |
| Cellular Function and Maintenance | | | > | > | | |
| Gene Expression | | T | | | | |
| Cellular Response to Therapeutics | | ۲ | | | | |
| Lipid Metabolism | \rightarrow | | | | | |
| Vitamin and Mineral Metabolism | $\langle \cdot \rangle$ | ۲ | | | | |
| Molecular Transport | \rightarrow | | | | | |
| Carbohydrate Metabolism | | | | | | _ |
| | 0 1 | 0 | 20 | 3 | 0 | 40 |
| | Nu | m | ber of | f ger | ies | |

| Α | | | |
|-------|-----------------|--------|----------|
| | 1.01 2.85 | | |
| LogFC | LOGI | LogFC | |
| _09.0 | | _0g. 0 | |
| | NEB | | CHERP |
| | Protein_FAM86C1 | | GNAI1 |
| | ASIP NDD1 | | LSIVIT4A |
| | MT-PNP2 | | |
| | RHD | | CADM1 |
| | PGF | | RPL3 |
| | GPR151 | | PDE1C |
| | TSHR | | TMEM59 |
| | TNNT2 | | NPM1 |
| | RBM28 | | RPS24 |
| | KIAA1239 | | TSPAN16 |
| | ACYP1 | | CES3 |
| | NOVA1 | | PYCR2 |
| | SAMD4B | | CD2AP |
| | C2CD2 | | TRIM21 |
| | BMX | | FARSA |
| | ZDHHC18 | | GSPT2 |
| | IL37 | | XAGE1A |
| | ZNF184 | | MB2 |
| | C2orf83 | | ASS1 |
| | TRIM24 | | KIRREL2 |
| | ACIN1 | | HIR/ |
| | RBM41 | | DOCK9 |
| | BRTOR | | |
| | NCOAZ | | I DDC/6 |
| | TVPP1 | | NDUEA10 |
| | FLAC1 | | CD200 |
| | CCNB2 | | ADRA1B |
| | DEXI | | ATP5A1 |
| | SSR1 | | FKBP1A |
| | ZNF507 | | RTP4 |
| | FMO2 | | RBBP9 |
| | ZCCHC4 | | RALA |
| | HK1 | | AKAP17A |
| | MC3R | | MYOZ2 |
| | PSRC1 | | LAMTOR1 |
| | HLCS | | PRR11 |
| | C17orf53 | | GUCA1C |
| | CGGBP1 | | KLRC3 |
| | CAPN2 | | NBN |
| | PCDHB5 | | SPIB |
| | ADCY9 | | TBC1D2B |
| | KITLG | | PIK3R3 |
| | NOG | | IL24 |
| | SP2 | | ASF1A |
| | IIC3/ | | C110051 |
| | ADAMISL1 | | PRPC1 |
| | GPR52 | | POR |
| | C1orf56 | | PAFAH1P1 |
| | RNASEH2A | | GCC1 |
| | NOA1 | | SLMAP |
| | TIMM23 | | SLC48A1 |
| | PHF20L1 | | ASF1B |
| | GABPA | | PDE8B |
| | LRRC16A | | ITGA3 |
| | FGF5 | | MOG |
| | DHX8 | | SNRPD3 |
| | VN1R1 | | EIF2A |

Figure S2









В

Α

p-Actin

RTHS



С



prion + LV-control

prion + LV-control + cooling

prion + LV-shRNA-RTN3 + cooling

Figure S1. Transcriptional profiling following mild coldshock. Related to Figure 1

(A) Genes shown are those with a 2-fold change and a statistically significant difference between control and cooled conditions. Values represent the mean, normalised \log_2 ratio of transcript level in cold-shock versus control conditions.

(B) Functional classification of genes down-regulated at transcriptional level following cold shock. Biological functions associated with regulated genes, obtained from the Ingenuity Pathways Analysis. p-value (threshold p < 0.05) for each biological function are represented by the grey bar chart, number of genes per category is represented by the purple line.

Figure S2. Venn diagram of to show genome-wide changes on cold shock. Related to Figure 1, Figure S1 and Tables S1-S3

The Venn diagram shows the number of overlapping genes between polysomal association down-regulated and upregulated and the transcriptionally down-regulated lists.

Figure S3. Computational modelling to predict mRNAs that are insensitive to low levels of eEF2. Related to Figure 1F

The total rate of elongation is dependent on the processes of tRNA competition (that is completed by acceptance of the cognate tRNA and subsequent peptidyl transfer), and eEF2-catalysed ribosomal translocation. Under normal conditions, tRNA competition and translocation take a similar length of time for fast codons (which are decoded by abundant tRNAs). However, tRNA competition is much slower than translocation for slow codons (which are decoded by rarer tRNAs), as can be shown by detailed stochastic models of these processes.

(A) Mathematical modelling of *S. cerevisiae* peptidyl transfer times plotted for 3 individual codons, one of which is decoded by an abundant tRNA (AAA) whereas the other two are decoded by rare tRNAs (CGG and CCU). This constitutes the first step in translation elongation.

(B) The time for translocation, the second stage of elongation, is plotted as a function of eEF2 availability. Intracellular eEF2 concentrations are as for *S. cerevisiae*.

(C) To compare the effect of altered eEF2 availability on the total decoding time for an abundant and 2 rare codons we modified our model to simulate conditions of eEF2 ablation, where the translocation step becomes slower. These conditions disproportionally affect fast codons: at an eEF2 availability of 10% of full levels, fast codons are predicted to change their overall elongation rate by an order of magnitude, whereas slow codons change their overall elongation rate by less than two-fold. The change is expressed relative to the time taken at 100% eEF2 availability.

Figure S4. RTN3 is a slow elongating mRNA. Related to Figure 2

(A) HEK293 cells were treated with harringtonine to block initiation phase of translation. After 3 minutes, ribosome run-off from the mRNAs was blocked by addition of cycloheximide. Sucrose density gradient ultra-centrifugations were performed (as described in the materials and methods section). Plots show the distribution of RNA within subpolysomes (40S, 60S and 80S) and polysomes as indicated. RNA was isolated from fractions, which were then subjected to qPCR for β -Actin and RTN3 mRNAs. qPCR for 18S rRNA is used as a control. Error bars show standard deviation within a representative experiment.

(B) The efficiency of the ribosomes to run off the β -Actin and RTN3 mRNAs is calculated from 2 independent experiments. Error bars show standard deviation. The elongation rate of RTN3 mRNA is slower than the control in support of the model.

Figure S5. Protein changes upon cooling. Related to Figures 2,4 and 5

(A) HEK293 cells were treated with 100mg/ml cycloheximide, to block protein synthesis. After 2, 6 or 24 hours, protein extracts were analysed by Western Blots to assess the levels of RTN3 and c-Myc. RTN3 protein levels are unaffected by degradation at least up to 24 hours and therefore has a relatively long half life. In contrast c-Myc protein, which has a short half-life is rapidly degraded.

(B) Whole cell lysates from either HEK293, or SHSY5Y cells incubated at 37°C or 32°C for 24 hours, were analysed by western blot for poly-ubiquitinated proteins. Vinculin is used as a loading control. The data show that cooling reduces the level of steady state poly-ubiquitinated proteins. Bar graphs show quantification of polyubiquitin using data from 3 independent experiments. Error bars represent standard error.

(C) LV-shRNA-RTN3 accelerated synapse loss in the CA1 hippocampal region. Representative electron micrographs are shown, pseudo-coloured for ease of synapse identification: presynaptic, dark pink; postsynaptic light pink. Bar chart quantification is shown. Data represents are mean \pm SEM. T-test *** *P* < 0.0001. Scale bar 1 µm (D) In prion-infected mice total PrP and PrP^{Sc} levels do not alter after early cooling to 16–18°C following treatment with LV-shRNA-RTN3. PrP and PrP^{Sc} tested in terminal mice. Representative western blots are shown for 3 mice per temperature and time point and a single uninfected control mouse.

Top Networks

| | • | |
|----|---|-------|
| ID | Associated Network Functions | Score |
| 1 | Cell Death, Cancer, Endocrine System Disorders | 49 |
| 2 | Gastrointestinal Disease, Hepatic System Disease, Cell -To-Cell Signaling and Interaction | 38 |
| 3 | Hereditary Disorder, Metabolic Disease, Embryonic Development | 31 |
| 4 | Cell Cycle, Cell Death, Cell -To-Cell Signaling and Interaction | 24 |
| 5 | Cancer, Hereditary Disorder, Reproductive System Disease | 20 |

Molecular and Cellular Functions

| Name | p-value | # Molecules |
|--|---------------------|-------------|
| Cellular Assembly and Organization | 5.69E-05 - 2.96E-02 | 23 |
| DNA Replication, Recombination, and Repair | 5.69E-05 - 2.96E-02 | 10 |
| Amino Acid Metabolism | 1.10E-04 - 3.48E-02 | 5 |
| Small Molecule Biochemistry | 1.10E-04 - 3.48E-02 | 19 |
| Cell Death | 3.51E-04 - 3.54E-02 | 15 |

Top Canonical Pathways

| Name | p-value | Ratio |
|---|----------|----------------|
| G-Protein Coupled Receptor Signaling | 4.98E-05 | 12/526 (0.023) |
| Relaxin Signaling | 1.21E-03 | 5/157 (0.032) |
| Melanocyte Development and Pigmentation Signaling | 1.68E-03 | 4/92 (0.043) |
| cAMP-mediated signaling | 1.75E-03 | 6/219 (0.027) |
| mTOR Signaling | 5.54E-03 | 5/209 (0.024) |

Table S1. Related to Figure 1D and E and Figure S1.

Top significant networks, molecular functions and canonical pathways associated with the differentially expressed genes identified by Ingenuity Pathway Analysis.

| Gene Name | logFC | P.Value |
|--------------------|-------------|------------|
| hsa-miR-346 | 0.41596256 | 0.04347048 |
| hsa-miR-147 | 0.38747801 | 0.04702239 |
| hsa-miR-424_MM1 | 0.261651 | 0.02224146 |
| hsa-miR-551a | 0.23395519 | 0.01667835 |
| hsa-miR-590-5p | 0.20676563 | 0.0436902 |
| hsa-miR-130a_MM2 | 0.1867928 | 0.01700183 |
| hsa-miR-223 | 0.14894424 | 0.03641048 |
| hsa-miR-29c* | 0.14838916 | 0.02312406 |
| hsa-miR-607 | 0.14222777 | 0.04783652 |
| hsa-miR-211 | 0.1219513 | 0.03575188 |
| hsa-miR-371-3p_MM2 | -0.14289755 | 0.02901324 |
| hsa-miR-449b | -0.1587873 | 0.02097055 |
| hsa-miR-320 | -0.17020202 | 0.03939156 |
| hsa-miR-20a | -0.1789382 | 0.02536781 |
| hsa-miR-200b | -0.18473276 | 0.03840512 |
| hsa-miR-518b | -0.23544463 | 0.04298777 |
| hsa-miR-20b | -0.23634331 | 0.02701268 |
| hsa-miR-296-5p | -0.2397331 | 0.00506562 |
| hsa-miR-519e* | -0.24763121 | 0.02028128 |
| hsa-miR-184 | -0.44333136 | 0.04380508 |

Table S2. miRNA profiling. Related to Figure 1 and Figure S1

miRNA profiling was performed on samples isolated from cells incubated at either 32°C or 37 °C. No miRNA expression had more than a 2-fold difference between cooled and control.

Decreased polysomal association

Top Networks

| ID | Associated Network Functions | Score |
|----|---|-------|
| 1 | Cell Death, Liver Damage, Lipid Metabolism | 49 |
| 2 | Nucleic Acid Metabolism, Small Molecule Biochemistry, Cellular Assembly and Organization | 32 |
| 3 | Connective Tissue Disorders, Dermatological Diseases and Conditions, Developmental Disorder | 32 |
| 4 | Reproductive System Development and Function, Tissue Morphology, Tissue Development | 21 |
| 5 | Infectious Disease, Molecular Transport, Renal and Urological System Development and Function | 8 |

Molecular and Cellular Functions

| Name | p-value | # Molecules |
|--|---------------------|-------------|
| DNA Replication, Recombination, and Repair | 3.18E-04 - 4.64E-02 | 6 |
| Carbohydrate Metabolism | 2.88E-03 - 3.50E-02 | 7 |
| Cell Cycle | 3.95E-03 - 4.64E-02 | 6 |
| Cell Death | 3.95E-03 - 4.92E-02 | 18 |
| Cell-To-Cell Signaling and Interaction | 3.95E-03 - 4.26E-02 | 6 |

Top Canonical Pathways

| Name | p-value | Ratio |
|--------------------------------|----------|---------------|
| Induction of Apoptosis by HIV1 | 1.71E-03 | 3/66 (0.045) |
| Mitochondrial Dysfunction | 1.56E-02 | 3/174 (0.017) |
| CD27 Signaling in Lymphocytes | 1.73E-02 | 2/57 (0.035) |
| Oxidative Phosphorylation | 1.89E-02 | 3/159 (0.019) |
| Ubiquinone Biosynthesis | 3.12E-02 | 2/114 (0.018) |

Table S3. Translational profiling. Related to Figure 1 and Figure S1

Functional classification of genes down-regulated at translational level following cold shock. Top significant networks, molecular functions and canonical pathways associated with the differentially expressed genes identified by Ingenuity Pathway Analysis.

| "Slow" mRNAs, less polysomally associated | Accession | Cellular Component (GO terms) | Biological Process (GO terms) |
|--|---|--|--|
| PLXND1 | NM_015103 | GO:0005887 = integral component of plasma membrane | GO:0071526 = semaphorin-plexin signaling pathway |
| ATP5F1 | NM_001688 | GO:0000276 = mitochondrial proton-transporting ATP synthase complex GO:0005743 = mitochondrial inner membrane | GO:0015986 = ATP synthesis coupled proton transport |
| RECK | NM_021111 | GO:0005886 = plasma membrane GO:0031225 = anchored component of membrane | GO:0030198 = extracellular matrix organization |
| RTN3 | NM_001265589 | GO:0000139 = Golgi membrane GO:0005789 = ER membrane | GO:0006915 = apoptotic process GO:0071786 = ER tubular network organization |
| FOXN3 | NM_001085471 | GO:0005634 = nucleus | GO:0006355 = regulation of transcription |
| NDUFA9 | NM_005002 | GO:0005743 = mitochondrial inner membrane | GO:0006120 = mitochondrial electron transport |
| JTB | NM_006694 | GO:0005887 = integral component of plasma membrane | GO:0008637 = apoptotic mitochondrial changes |
| CHPT1 | NM_020244 | GO:0000139 = Golgi membrane | GO:0006656 = phosphatidylcholine biosynthetic process |
| NOG | NM_005450 | GO:0005576 = extracellular region | GO:0001701 = in utero embryonic development |
| CYP2E1 | NM_000773 | GO:0000139 = Golgi membrane GO:0031227 = intrinsic component of ER membrane | GO:0019373 = epoxygenase P450 pathway |
| HSPA5/BIP | NM_005347 | GO:0005788 = ER lumen GO:0034663 = ER chaperone complex GO:0030176 = integral component of ER membrane | GO:0030968 = ER unfolded protein response |
| KDM1A | KDM1A NM_001009999 GO:0005634 = nucleus GO:0005667 = transcription factor complex GO:000 | | GO:0000122 = negative regulation of transcription |
| GPX4 NM_001039847 GO:0005739 = mitochondrion GO:0005829 = cytosol GO:0006749 = glutathione metabolic | | GO:0006749 = glutathione metabolic process | |
| CPB1 | NM_001871 | GO:0005576 = extracellular region | GO:0006508 = proteolysis |
| SLC25A5 | NM_001152 | GO:0005743 = mitochondrial inner membrane GO:0005887 = integral component of plasma membrane | GO:1901029 = negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway |
| HAVCR1 | NM_001099414 | GO:0016021 = integral component of membrane | GO:0046718 = viral entry into host cell |
| SIVA1 | NM_006427 | GO:0005634 = nucleus GO:0005739 = mitochondrion | GO:1901030 = positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway |
| RNF13 | NM_007282 | GO:0000139 = Golgi membrane GO:0005789 = ER membrane GO:0016021 = integral component of membrane | GO:0051865 = protein autoubiquitination |
| CCT6A | NM_001762 | GO:0005832 = chaperonin-containing T-complex | GO:0006457 = protein folding |
| AATK NM_004920 GO:0005783 = ER GO:0044295 = axonal growth cone GO:0016021 = integral component of membrane GO:0007420 = brain development GO:0030517 = negative regulation of axon extr | | GO:0007420 = brain development GO:0030517 = negative regulation of axon extension | |

Table S4. Related to Figure 1 and Figure S1 and 2

A list of mRNAs less polysomally associated following cooling and that contained poorly optimised codons. Interestingly, many of these proteins are membrane associated.

| | Relative to Ala-IGC | | |
|----------|---------------------|--------|--|
| | Average | St Dev | |
| Ala-IGC | 1.00 | 0.0000 | |
| Ala-hGC | 3.58 | 0.2675 | |
| Arg-ICG | 5.10 | 1.3591 | |
| Arg-yCG | 3.32 | 0.7445 | |
| Arg-CCT | 2.19 | 0.6331 | |
| Arg-TCT | 2.76 | 0.3822 | |
| Asn-GTT | 6.45 | 1.7786 | |
| Asp-GTC | 10.61 | 4.4094 | |
| Cys-GCA | 11.42 | 3.9288 | |
| Gln-yTG | 10.19 | 3.4363 | |
| Glu-yTC | 12.41 | 5.1321 | |
| Glu-TTC | 8.71 | 2.4103 | |
| Gly-sCC | 8.32 | 1.5825 | |
| Gly-TCC | 11.21 | 3.4035 | |
| His-GTG | 3.96 | 0.4647 | |
| lle-rAT | 4.50 | 0.2619 | |
| lle-TAT | 1.92 | 0.0034 | |
| Leu-wAG | 4.61 | 0.7049 | |
| Leu-CAG | 7.42 | 0.5317 | |
| Leu-CAA | 4.77 | 0.4465 | |
| Leu-TAA1 | 1.46 | 0.0800 | |
| Lys-CTT | 8.36 | 3.0412 | |
| Lys-TTT1 | 7.69 | 2.1075 | |
| Met-i | 10.76 | 2.8043 | |
| Met-e | 7.48 | 0.7467 | |
| Phe-GAA | 7.73 | 0.0323 | |
| Pro-hGG | 5.03 | 1.4005 | |
| Sec-TCA2 | 0.76 | 0.1401 | |
| Ser-CGA | 3.46 | 1.1038 | |
| Ser-wGA | 3.38 | 0.4407 | |
| Ser-GCT | 4.88 | 1.7870 | |
| Thr-mGT | 7.28 | 1.3873 | |
| Thr-TGT1 | 4.09 | 0.7747 | |
| Thr-CGT2 | 1.04 | 0.2128 | |
| Trp-CCA | 6.83 | 0.3551 | |
| Tyr-GTA | 3.35 | 1.0032 | |
| Val-mAC | 9.12 | 1.2182 | |
| Val-TAC | 3.46 | 0.2984 | |

Table S5. tRNA concentration. Related to Figure 1 and Figure S3

A table to show the relative tRNA expression in HEK-293 cells.

| | Average Speed |
|-----------|---------------|
| Gene Name | on initial 20 |
| | codon stretch |
| | (codons/sec) |
| 'PLXND1' | 1.362297336 |
| 'ATP5F1' | 1.442855541 |
| 'RECK' | 1.510570878 |
| 'RPAP3' | 1.521085566 |
| 'RTN3' | 1.565637314 |
| 'FOXN3' | 1.586957801 |
| 'NDUFA9' | 1.601096139 |
| 'JTB' | 1.615165029 |
| 'CHPT1' | 1.615872734 |
| 'NOG' | 1.625053918 |
| 'CYP2E1' | 1.649410682 |
| 'HSPA5' | 1.652127552 |
| 'KDM1A' | 1.661677058 |
| 'GPX4' | 1.676822335 |
| 'CPB1' | 1.688679086 |
| 'SLC25A5' | 1.707429543 |
| 'KCNJ13' | 1.708290697 |
| 'HAVCR1' | 1.7099814 |

Table S6. Decoding speed of first 20 amino acids. Related to Figure 1,Figure 2 and Figure S4

Calculation of the decoding speed of the first 20 codons of the mRNAs identified as associated with a decreased number of ribosomes following cooling. The table lists the top slowest 25%. This window of 20 codons was chosen because ribosome speed on the first codons following the start codon can be analysed without taking ribosome queuing effects into account, which would reduce the confidence of any predictions on speed properties. This analysis would identify a minimal sub-set of mRNAs where expression levels are controlled via the elongation stage, although it would also miss many such mRNAs where the speed-limiting sequence is located further downstream.

Supplemental Experimental Procedures

Antibodies

Antibodies were purchased from Sigma (β -Actin), Cell Signalling (Noggin, GBBR1, LDHA, eIF2 α , eEF2), Abcam (RBM3 (human), RTN3), Santa Cruz (GAPDH, c-Myc), Proteintech (CIRP, RBM3 (mouse)) and D-GEN (ICSM35 for PrP).

Plasmids

The 5'UTR of *RTN3* was amplified by PCR from HEK293 cell cDNA using the following primer pairs:

RTN3 5'UTR fw gactagGCATGCGCGCGCGCGCGC

RTN3 5'UTR rv catgccatgGGCTACGCGAGCGAG

These sequences were cloned into pGL3 (Promega) upstream of luciferase firefly between *Spe*I and *Nco*I restriction enzyme sites and were verified by sequencing.

Transfection

SiRNAs (siGENOME Non-Targeting siRNA Pool #1 and SMARTpool: ON-TARGETplus RBM3 siRNA, Dharmacon) transfection were performed using DharmaFECT 1 (Dharmacon) transfection reagent at a final concentration of 100 nM according to manufacturer instructions, after 24h cells were split and transfected with luciferase constructs 24h later.

DNA transfections: These were performed using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions and cells harvested 24 hours after transfection. Luciferase activity was measured using a dual luciferase assay system from Promega. Co-transfection with *Renilla* luciferase was used as an internal normalisation control.

Lentivirus: Mouse RBM3 isoform-2 (NM_001166410.1) overexpression was induced using the pLenti CAMKII (RBM3) Rsv (GFPBsd) plasmid [S1]. Mouse RTN3 (NM_053076.3) overexpression was induced with pLenti CAMKII (RBM3) Rsv (GFPBsd) plasmid (Gen Target Inc). The pLenti CAMKII (empty) Rsv (GFPBsd) plasmid was used as control.

RTN3 down regulation was achieved by using pLenti H1 shRNA (m RTN3) sequence #3 Rsv (GFPBsd). This plasmid contains the following shRNA-RTN3 sense, antisense and loop sequences (sequence #3:

5'TATGTTGGGATTGCCCGGGATcgagATCCCGGGCAATCCCAACATA 3'. The

pLenty H1 shRNA (negative control) Rsv (GFPBsd) containing the sequence

5'-GTCTCCACGCGCAGTACATTTcgagAAATGTACTGCGCGTGGAGAC-3'

was used as control. Viruses were used with a final titre of 0.6-1.5 x 108 TU. Prion

infected mice were injected with lentiviruses at 2 w.p.i.

RT-PCR Primers

Mouse:

| mRBM3 RT fw | ACTCTTCGTAGGAGGGCTCA |
|--------------|----------------------|
| mRBM3 RT rev | CTCAGAGATAGGCCCAAAGC |
| mRTN3 RT fw | AGGCCTACTTGGATGTGGAC |
| mRTN3 RT rev | CAGCTTCAAGGAGTCAACCA |
| Human: | |

| hACTIN RT fw | GTACCACTGGCATCGTGATGG |
|---------------|-----------------------|
| hACTIN RT rev | CCGCTCATTGCCAATGGTGAT |
| hGAPDH RT fw | GCACAGTCAAGGCCGAGAAT |
| hGAPDH RT rev | GCCTTCTCCATGGTGGTGAA |
| RBM3 h RT fw | GCTATGGGAGTGGCAGGTAT |
| RBM3 h RT rev | GTAGCGGTCATAACCACCCT |

Protein synthesis rate determination

Cells were methionine starved for 30 minutes before addition of medium containing $40 \,\mu\text{Ci/ml Trans}^{35}\text{S}$ -Label. After 30 minutes incubation, cells were harvested, washed and lysed in passive lysis buffer (Promega). Hippocampal slices were prepared. Slices were allowed to recover in normal artificial cerebrospinal fluid buffer while being

oxygenated either at 37°C or at 26°C for 1h, incubated with ³⁵S methionine label for 1h, then homogenized. Cells and slices lysates were centrifuged and protein precipitated from the supernatant with 10% trichloroacetic (TCA). Following washes with 70% IMS and 100% acetone, ³⁵S-methionine incorporation was determined by scintillation counting. Counts were normalised to total protein in the cell lysates as determined by Bradford assay (Bio-Rad).

Western Blotting

Cells and hippocampi lysed in protein lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1% Na deoxycholate, 0.1% SDS and 125 mM sucrose) supplemented with Phos-STOP and protease inhibitors (Roche), followed by centrifugation and quantification. PrP^{Sc} was detected after Proteinase K digestion. Lysates were subject to electrophoresis on SDS-polyacrylamide gels and the proteins transferred to PDVF or Nitrocellulose membranes (Bio-Rad). Blots were probed with the relevant antibodies and HRP-conjugated secondary antibodies, detected by ECL Prime western blotting detection reagent (GE Healthcare). Quantification was performed using ImageJ software.

Northern Blot analysis

RNA was separated by electrophoresis through a 1% formaldehyde-containing agarose gel and then transferred to Zeta-probe membrane (Bio-Rad) overnight in 20XSSC buffer and fixed by UV crosslinking. DNA hybridization probes were prepared from 50 ng DNA template and radiolabeled with αP^{32} CTP by random priming using Klenow enzyme (New England Biolabs). After overnight hybridisation with the radioactive probe in Church-Gilberts Solution (140 mM Na₂PO₄, 70 mM NaH₂PO₄, 7% SDS) at 55°C, the membrane was washed twice with 2X SSC, 0.1% SDS, twice with 0.5X SSC, 0.1% SDS and twice with 0.1X SSC, 0.1% SDS.

Sucrose density gradient analysis

Cells were treated with cycloheximide at 100 µg/ml for 3 minutes prior to harvesting, pellets lysed in gradient buffer (300 mM NaCl, 15 mM MgCl2, 15 mM Tris pH 7.5 containing 1 mg/ml heparin sulphate and 100 µg/ml cycloheximide) plus 1% Triton X-100. The hippocampal tissues were dissected in ice-cold gradient buffer, and then homogenized in gradient buffer containing RNase inhibitors and 1.2% TritonX-100. Post nuclear supernatants were layered on 10-60% (w/v) sucrose gradients of gradient buffer. Gradients were centrifuged at 38,000 rpm for 2 hours at 4°C in a SW40Ti rotor (Beckman Coulter) then separated through a live optical density (OD) 254 nm UV spectrometer (Isco). Gradients were fractionated with continuous monitoring at 254 nm. Fractions of equal volume were collected directly into guandine-HCl, to give a final concentration of 5.8 M, and the RNA precipitated by addition of 1 volume of 100% ethanol. The RNA was resuspended in water and further purified by sodium acetate/ethanol precipitation.

Transcriptional Profiling

The human cDNA microarrays contained a set of total human cDNA clones. Total RNA from cells cultured either 24 hr at 37°C or at 32°C was extracted using TRIZOL (Invitrogen). Fluorescently labelled DNA probes were generated from equal proportions of RNAs (approximately 5µg) of 37°C RNA (Cy5) and 32°C RNA (Cy3) and hybridised to the arrays as described previously/ Microarray slides were scanned using a GenePix 4200B microarray scanner and GenePix Pro 6.0 software (Axon Instruments).

miRNA microarray

To investigate change in miRNA expression, miRNA microarray was carried out using a miRNA probe set from Exiqon (Exiqon, Vedbaek, Denmark) printed in-house. RNA samples were labelled using FlashTagTM RNA labelling kit from Genisphere according to manufacturer instruction. Briefly 1.5ug of RNA was polyA tailed 15 min at 37°C followed by the labelling with a fluorophore (control with alexa 550 and coldshock with alexa-647) using T4 DNA ligase at room temperature for 30 min and then hybridised to the array at 52°C overnight. Following hybridisation slides were washed for 2 min in each wash solution (wash 1: 2X SSC, 0.2 %SDS; wash 2: 2X SSC; wash 3: 0.2X SSC), dried by centrifugation and scanned using a GenePix 4200B microarray scanner and GenePix Pro 6.0 software (Axon Instruments).

Analysis of Microarray Data

GenePix Pro 6.0 was used to quantify fluorescence intensities for individual spots on the microarray. All statistical analysis was performed in the statistical environment R, version 2.6.1 and the Limma package [S2]. Within-array normalisation using the print tip loess method and between-array normalisation using the scale method were performed on the data. Differentially expressed genes were then identified using the limFit and topTable functions. Genes which showed a fold change >2 and P-value < 0.05 were considered as potential candidates for altered distribution following coldshock at a statistically significant level. Once candidate genes were identified the sequence of the accession attached to each clone ID was search against the NCBI nucleotide database using nucleotide BLAST, with an E-value cut off of 0.001. The best match Refseq sequence(s) were chosen automatically for each clone ID. If no RefSeq hits were retrieved, non-RefSeq hits were checked manually for potential matches.

Immunoprecipitation reactions

Post-nuclear extracts were incubated with either anti-RBM3 antibody or IgG coated protein G magnetic beads which were washed (250 mM Tris pH 7.4, 300 mM NaCl, 5

mM MgCl₂, 0.5% NP40, 1 mM DTT and then resuspended in 200 µl buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM MgCl₂, 0.05% NP40) containing 0.1% SDS and 60 µg proteinase K. RNA was extracted using Trizol LS (Invitrogen) according to manufacturer instructions.

Supplemental References

S1. Peretti, D., Bastide, A., Radford, H., Verity, N., Molloy, C., Martin, M.G., Moreno, J.A., Steinert, J.R., Smith, T., Dinsdale, D., et al. (2015). RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration. Nature 518, 236-239.

S2. Smyth, G.K. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol *3*, Article3.